Benzotriazole: An overview on its versatile biological behavior

European Journal of Medicinal Chemistry

Volumn 97, Issue 1, 2015, Pages 612-648

  Briguglio, I ^a   Piras, S ^a   Corona, P ^a   Gavini, E ^a   Nieddu, M ^a   Boatto, G ^a   Carta, A ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

1H benzo d 1 2 3 triazole; Anti tubulin; Antimicrobial; Antimycobacterial; Antiprotozoal; Antiviral

Indexed keywords

ALKANOIC ACID; ANTHELMINTIC AGENT; ANTIFUNGAL AGENT; ANTIMYCOBACTERIAL AGENT; ANTINEOPLASTIC AGENT; ANTIPARASITIC AGENT; ANTIVIRUS AGENT; BENZOTRIAZOLE DERIVATIVE; CASEIN KINASE II; CHOLERETIC AGENT; COORDINATION COMPOUND; DOPAMINE RECEPTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; POTASSIUM CHANNEL STIMULATING AGENT; PROTEIN SERINE THREONINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; PROTEIN TYROSINE PHOSPHATASE 1B INHIBITOR; SEROTONIN RECEPTOR; BENZOTRIAZOLE; TRIAZOLE DERIVATIVE;

ANTHELMINTIC ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIEMETIC ACTIVITY; ANTIFUNGAL ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; BIOLOGICAL ACTIVITY; CHEMICAL STRUCTURE; DRUG SYNTHESIS; HUMAN; MEDICAL RESEARCH; MUTAGENIC ACTIVITY; NONHUMAN; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG DEVELOPMENT; PROCEDURES;

ANIMALS; DRUG DISCOVERY; HUMANS; TRIAZOLES;

EID: 84937407143     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.09.089     Document Type: Review

References (317)

1. K.P. Barot, S. Nikolova, I. Ivanov, M.D. Ghate, Novel research strategies of benzimidale derivatives: a review, Mini Rev. Med. Chem. 13 (2013) 1421-1447.
2. Q.A. McKellar, E.W. Scott, The benzimidazole anthelmintic agents e a review, J. Vet. Pharmacol. Ther. 13 (1990) 223-247.
3. A.P. Piccionello, A. Guarcello, Bioactive compounds containing benzoxadiazole, benzothiadiazole, benzotriazole, Curr. Bioact. Compd. 6 (2010) 266-283.
4. B.V. Suma, N.N. Natesh, V. Madhavan, Benzotriazole in medicinal chemistry: an overview, J. Chem. Pharm. Res. 3 (2011) 375-381.
5. R. Kale, V. Prasad, P. Mohapatra, V. Tiwari, Recent developments in benzotriazole methodology for construction of pharmacologically important heterocyclic skeletons, Monatsh. für Chem.-Chem. Mon. 141 (2010) 1159-1182.
6. A.R. Katritzky, S.A. Henderson, B. Yang, Applications of benzotriazole methodology in heterocycle ring synthesis and substituent introduction and modification, J. Heterocycl. Chem. 35 (1998) 1123-1159.
7. A.R. Katritzky, X. Lan, J.Z. Yang, O.V. Denisko, Properties and synthetic utility of N-substituted benzotriazoles, Chem. Rev. 98 (1998) 409-548.
8. A.R. Katritzky, L. Khelashvili, P.P. Mohapatra, P.J. Steel, Efficient N-aroylation of substituted indoles with N-aroylbenzotriazoles, Synthesis 23 (2007) 3673-3677.
9. A.R. Katritzky, P. Angrish, E. Todadze, Chiral acylation with N-(protected aaminoacyl) benzotriazoles for advantageous synthesis of peptides and peptide conjugates, Synlett (2009) 2392-2411.
10. A.R. Katritzky, B.V. Rogovoy, Benzotriazole: an ideal synthetic auxiliary, Chemistry 9 (2003) 4586-4593.
11. X. Wang, Y. Liu, Y. Zhang, Elimination of benzotriazolyl group in N-(a-benzotriazol-1-ylalkyl)amides and N-(a-benzotriazol-1-ylalkyl)sulfonamides: their self-coupling and cross-coupling reactions with carbonyl compounds, Tetrahedron 59 (2003) 8257-8263.
12. A.R. Katritzky, S. Rachwal, G.J. Hitchings, Benzotriazole: a novel synthetic auxiliary, Tetrahedron 47 (1991) 2683-2732.
13. A.R. Katritzky, K. Manju, S.K. Singh, N.K. Meher, Benzotriazole mediated amino-, amido-, alkoxy-and alkylthio-alkylation, Tetrahedron 61 (2005) 2555-2581.
14. A.R. Katritzky, S.R. Tala, N.E. Abo-Dya, K. Gyanda, D. El-Gendy Bel, Z.K. Abdel-Samii, P.J. Steel, Selective synthesis and structural elucidation of S-acyl-and N-acylcysteines, J. Org. Chem. 74 (2009) 7165-7167.
15. W.M. Berhanu, M.A. Ibrahim, G.G. Pillai, A.A. Oliferenko, L. Khelashvili, F. Jabeen, B. Mirza, F.L. Ansari, I. Ul-Haq, S.A. El-Feky, A.R. Katritzky, Similarity analysis, synthesis, and bioassay of antibacterial cyclic peptidomimetics, Beilstein J. Org. Chem. 8 (2012) 1146-1160.
16. A.R. Katritzky, B.V. Rogovoy, C. Chassaing, V. Vvedensky, Di(benzotriazol-1-yl)methanimine: a new reagent for the synthesis of tri-and tetrasubstituted guanidines, J. Org. Chem. 65 (2000) 8080-8082.
17. A.R. Katritzky, V. Rogovoy, V.Y. Vvedensky, K. Kovalenko, P.J. Steel, V.I. Markov, B. Foroode, Synthesis of N, N-disubstituted 3-amino-1, 2, 4-triazoles, Synthesis 6 (2001) 897-903.
18. A.R. Katritzky, L. Xie, D. Toader, L. Serdyuk, General and efficient carbon insertion route to one-carbon-homologated alpha-aryl, alpha-Alkenyl, alpha-alkoxy, and alpha-phenylthio alkyl ketones, J. Am. Chem. Soc. 117 (1995) 12015-12016.
19. G. Boche, P. Andrews, K. Harms, M. Marsch, K.S. Rangappa, M. Schimeczek, C. Willeke, Crystal and electronic structure of stable nitrenium ions. A comparison with structurally related carbenes, J. Am. Chem. Soc. 118 (1996) 4925-4930.
20. S. Talukdar, R.J. Chen, C.T. Chen, L.C. Lo, J.M. Fang, Polymer-supported benzotriazoles as catalysts in the synthesis of tetrahydroquinolines by condensation of aldehydes with aromatic amines, J. Comb. Chem. 3 (2001) 341-345.
21. D. Davis, Benzotriazole, a plant-growth regulator, Science 120 (1954) 989.
22. V. Picci, Effect of benzotriazole and of 2 benzotriazolylacetic acids on plant growth, Farm. Sci. 21 (1966) 172-177.
23. F. Sparatore, M.I. La Rotonda, G. Paglietti, E. Ramundo, C. Silipo, A. Vittoria, Benzotriazole derivatives active on plant growth. I. Preparation, characterization, and correlation between physicochemical properties and structure, Farm. Sci. 33 (1978) 901-923.
24. F. Sparatore, M.I. La Rotonda, E. Ramundo, C. Silipo, A. Vittoria, Effect of benzotriazole derivatives on plant growth. II, Farm. Sci. 33 (1978) 924-944.
25. G. Paglietti, P. Sanna, A. Carta, F. Sparatore, I. Vazzana, A. Peana, M. Satta, Choleretic activity of 3-[ring substituted benzotriazol-1(2)-yl]alkanoic and alkenoic acids, Farm. Sci. 40 (1994) 693-702.
26. C.M. Jamkhandi, J.I. Disouza, Benzotriazole derivatives as antimicrobial agents, Asian J. Phar. Biol. Res. 2 (2012) 123-130.
27. F. Lopez-Vallejo, R. Castillo, L. Yepez-Mulia, J.L. Medina-Franco, Benzotriazoles and indazoles are scaffolds with biological activity against Entamoeba histolytica, J. Biomol. Screen. 16 (2011) 862-868.
28. P. Borowski, J. Deinert, S. Schalinski, M. Bretner, K. Ginalski, T. Kulikowski, D. Shugar, Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses, Eur. J. Biochem. 270 (2003) 1645-1653.
29. A. Beauchard, A. Jaunet, L. Murillo, B. Baldeyrou, A. Lansiaux, J.R. Cherouvrier, L. Domon, L. Picot, C. Bailly, T. Besson, V. Thiery, Synthesis and antitumoral activity of novel thiazolobenzotriazole, thiazoloindolo [3, 2-c]quinoline and quinolinoquinoline derivatives, Eur. J. Med. Chem. 44 (2009) 3858-3865.
30. X.M. Peng, G.X. Cai, C.H. Zhou, Recent developments in azole compounds as antibacterial and antifungal agents, Curr. Top. Med. Chem. 13 (2013) 1963-2010.
31. I. Chopra, The 2012 Garrod Lecture: discovery of antibacterial drugs in the 21st century, Antimicrob. Chemother. 68 (2013) 496-505.
32. H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, M. Scheld, B. Spellberg, J. Bartlett, Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America, Clin. Infect. Dis. : official Publ. Infect. Dis. Soc. Am. 48 (2009) 1-12.
33. F. Sparatore, F. Pagani, Aminoalkyl derivatives of benzotriazole, Farm. Sci. 17 (1962) 414-429.
34. F. Sparatore, F. Pagani, Aminoalkyl derivatives of benzotriazole. II, Farm. Sci. 20 (1965) 248-258.
35. F. Savelli, A. Pau, A. Boido, F. Sparatore, Aminoalkyl derivatives of benzotriazole and naphthotriazole, Boll. Chim. Farm. 127 (1988) 144-147.
36. A. Nuvole, P. Sanna, G. Paglietti, C. Juliano, S. Zanetti, P. Cappuccinelli, 1, 2, 3-triazolo [4, 5-f]quinolines. II. Preparation and antimicrobial evaluation of 6-ethyl-6, 9-dihydro-1(2)(3)-R-1(2) (3)H-triazolo [4, 5-f]quinolin-9-one-8-carboxylic acids as anti-infectives of the urinary tract (1), Farm. Sci. 44 (1989) 619-632.
37. P. Sanna, A. Carta, G. Paglietti, S. Zanetti, G. Fadda, 1, 2, 3-Triazolo [4, 5-h] quinolines. III. Preparation and antimicrobial evaluation of 4-ethyl-4, 7-dihydro-1(2)H Triazolo [4, 5-h]quinolin-7-one-6-carboxylic acids as anti infectives of the urinary tract, Farm. Sci. 47 (1992) 1001-1019.
38. F. Al-Omran, A.A. El-Khair, R.M. Mohareb, Synthesis and biological effects of new derivatives of benzotriazole as antimicrobial and antifungal agents, J. Heterocycl. Chem. 39 (2002) 877-883.
39. A. Rauf, S. Gangal, Facile one-pot synthesis of N-acyl-1H-1, 2, 3-benzotriazoles from internal and terminal olefinic fatty acids and their antimicrobial screening, J. Oleo Sci. 57 (2008) 453-457.
40. M. Purohit, S.K. Srivastava, Studies in aryloxylated benzotriazoles, Indian J. Pharm. Sci. 54 (1992) 25-27.
41. R.K. Upadhyay, S.D. Srivastava, Synthesis and studies on biologically active mono and biheterocycles, Indian J. Pharm. Sci. 57 (1995) 12-18.
42. C.M. Jamkhandi, J.I. Disouza, Synthesis and antimicrobial evaluation of 1HBenzotriazol-1-yl {2-hydroxy-5 [(E)phenyldiazenyl]phenyl}methanone derivatives, Int. J. Pharm. Pharm. Sci. 5 (2013) 225-228.
43. C.M. Jamkhandi, J.I. Disouza, Synthesis and antimicrobial evaluation of [(1Hbenzotriazol-1-ylacetyl) amino] acetic acid derivatives, Res. J. Pharm. Tech. 5 (2012) 1197-1200.
44. C.M. Jamkhandi, J.I. Disouza, Synthesis and antimicrobial evaluation of 2-(1H-1, 2, 3-Benzotriazol-1-yl)-N-Phenylacetamide derivatives, Res. J. Pharm. Tech. 5 (2012) 1072-1075.
45. Z. Ochal, M. Bretner, R. Wolinowska, S. Tyski, Synthesis and in vitro antibacterial activity of 5-halogenomethylsulfonyl-benzimidazole and benzotriazole derivatives, Med. Chem. 9 (2013) 1129-1136.
46. N.P. Singh, R. Kumar, D.N. Prasad, S. Sharma, O. Silakari, Synthesis and antibacterial activity of benzotriazole substituted acridines, Int. J. Biol. Chem. 5 (2011) 193-199.
47. K.Y. Saour, R.A. Atto, Synthesis of new levofloxacin derivatives and their biological activity, Pharm. Glob. (IJCP) 3 (2012) 1-5.
48. J. Das, C.V. Rao, T.V. Sastry, M. Roshaiah, P.G. Sankar, A. Khadeer, M.S. Kumar, A. Mallik, N. Selvakumar, J. Iqbal, S. Trehan, Effects of positional and geometrical isomerism on the biological activity of some novel oxazolidinones, Bioorg. Med. Chem. Lett. 15 (2005) 337-343.
49. P.P. Dixit, P.S. Nair, V.J. Patil, S. Jain, S.K. Arora, N. Sinha, Synthesis and antibacterial activity of novel (un)substituted benzotriazolyl oxazolidinone derivatives, Bioorg. Med. Chem. Lett. 15 (2005) 3002-3005.
50. K.C. Asati, S.K. Srivastava, S.D. Srivastava, Synthesis of 5-arylidene-2-aryl-3-(benzotriazoloacetamidyl)-1, 3-thiazolidin-4-ones as analegesic and antimicrobial agents, Indian J. Chem. 45B (2006) 526-531.
51. S. Nanjunda Swamy, Basappa, G. Sarala, B.S. Priya, S.L. Gaonkar, J. Shashidhara Prasad, K.S. Rangappa, Microwave-assisted synthesis of Nalkylated benzotriazole derivatives: antimicrobial studies, Bioorg. Med. Chem. Lett. 16 (2006) 999-1004.
52. S. Demirayak, K. Benkli, K. Guven, Synthesis of some 3-arylamino-5-aryloxymethyl [1, 2, 4]triazole derivatives and their antimicrobial activity, Pharm. Acta Helv. 72 (1998) 285-290.
53. N.A. Meanwell, Synopsis of some recent tactical application of bioisosteres in drug design, J. Med. Chem. 54 (2011) 2529-2591.
54. R. Ramachandran, M. Rani, S. Senthan, Y.T. Jeong, S. Kabilan, Synthesis, spectral, crystal structure and in vitro antimicrobial evaluation of imidazole/benzotriazole substituted piperidin-4-one derivatives, Eur. J. Med. Chem. 46 (2011) 1926-1934.
55. B.V. Suma, N.N. Natesh, C.H.S. Venkataramana, J. Jays, V. Madhavan, Synthesis and antibacterial of some new 1, 2, 3 benzotriazoles derivatives containing pyrazolidinedione moieties, Int. J. Pharm. Pharm. Sci. 4 (2012) 169-173.
56. B. Al-Saleh, M.A. El-Apasery, M.H. Elnagdi, Synthesis of new azoyl azoles and azinyl azoles, J. Heterocycl. Chem. 42 (2005) 483-490.
57. H.A. Elbadawy, A.F. Elshahat, G.M.H. Ahmed, Ligating behavior of some Sulphur containing benzotriazole derivatives towards some transition metal ions and their biological effect, Life Sci. J. 10 (2013) 3719-3724.
58. R.J. Pagliero, S. Lusvarghi, A.B. Pierini, R. Brun, M.R. Mazzieri, Synthesis, stereoelectronic characterization and antiparasitic activity of new 1-benzenesulfonyl-2-methyl-1, 2, 3, 4-tetrahydroquinolines, Bioorg. Med. Chem. 18 (2010) 142-150.
59. R.J. Pagliero, A.B. Pierini, R. Brun, M.R. Mazzieri, Design, synthesis and 3-D characterization of 1-Benzenesulfonyl-1, 2, 3, 4-Tetrahydroquinolines as lead scaffold for antiparasitic drug, Lett. Drug Des. Discov. 7 (2010) 461-470.
60. L.S. Hergert, M.J. Nieto, M.C. ecerra, I. Albesa, M.R. Mazzieri, Synthesis of NBenzenesulfonylbenzotriazole derivatives, and evaluation of their antimicrobial activity, Lett. Drug Des. Discov. 5 (2008) 313.
61. A.R. Katritzky, N. Shobana, J. Pernak, A.S. Afridi, W.-Q. Fan, Sulfonyl derivatives of benzotriazole: Part 1. A novel approach to the activation of carboxylic acids, Tetrahedron 48 (1992) 7817-7822.
62. M.C. Becerra, N. Guinazu, L.Y. Hergert, A. Pellegrini, M.R. Mazzieri, S. Gea, I. Albesa, In vitro activity of N-benzenesulfonylbenzotriazole on Trypanosoma cruzi epimastigote and trypomastigote forms, Exp. Parasitol. 131 (2012) 57-62.
63. R. Szyszka, N. Grankowski, K. Felczak, D. Shugar, Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources, Biochem. Biophys. Res. Commun. 208 (1995) 418-424.
64. K. Kopanska, A. Najda, J. Zebrowska, L. Chomicz, J. Piekarczyk, P. Myjak, M. Bretner, Synthesis and activity of 1H-benzimidazole and 1H-benzotriazole derivatives as inhibitors of Acanthamoeba castellanii, Bioorg. Med. Chem. 12 (2004) 2617-2624.
65. L. Chomicz, M. Padzik, Z. Graczyk, B. Starosciak, T.K. Graczyk, A. Naprawska, G. Oledzka, B. Szostakowska, Acanthamoeba castellanii: in vitro effects of selected biological, physical and chemical factors, Exp. Parasitol. 126 (2010) 103-105.
66. J.H. Rex, M.G. Rinaldi, M.A. Pfaller, Resistance of Candida species to fluconazole, Antimicrob. Agents Chemother. 39 (1995) 1-8.
67. P. Escribano, S. Recio, T. Pelaez, M. Gonzalez-Rivera, E. Bouza, J. Guinea, In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations, Antimicrob. Agents Chemother. 56 (2012) 174-178.
68. R.H. Rimawi, Y. Carter, T. Ware, J. Christie, D. Siraj, Use of voriconazole for the treatment of Paecilomyces lilacinus cutaneous infections: case presentation and review of published literature, Mycopathologia 175 (2013) 345-349.
69. N.D. Gaikwad, S.V. Patil, V.D. Bobade, Hybrids of ravuconazole: synthesis and biological evaluation, Eur. J. Med. Chem. 54 (2012) 295-302.
70. A. Cacciapuoti, D. Loebenberg, E. Corcoran, F. Menzel Jr., E.L. Moss Jr., C. Norris, M. Michalski, K. Raynor, J. Halpern, C. Mendrick, B. Arnold, B. Antonacci, R. Parmegiani, T. Yarosh-Tomaine, G.H. Miller, R.S. Hare, In vitro and in vivo activities of SCH 56592 (posaconazole), a new triazole antifungal agent, against Aspergillus and Candida, Antimicrob. Agents Chemother. 44 (2000) 2017-2022.
71. J.M. Trzaskos, W.D. Bowen, A. Shafiee, R.T. Fischer, J.L. Gaylor, Cytochrome P-450-dependent oxidation of lanosterol in cholesterol biosynthesis. Microsomal electron transport and C-32 demethylation, J. Biol. Chem. 259 (1984) 13402-13412.
72. P. Marichal, J. Gorrens, L. Laurijssens, K. Vermuyten, C. Van Hove, L. Le Jeune, P. Verhasselt, D. Sanglard, M. Borgers, F.C. Ramaekers, F. Odds, H. Vanden Bossche, Accumulation of 3-ketosteroids induced by itraconazole in azoleresistant clinical Candida albicans isolates, Antimicrob. Agents Chemother. 43 (1999) 2663-2670.
73. H.B. John, M.B.J. John, Wilson and Gisvold's Textbook of Organic Medicinal and Pharmaceutical Chemistry, eleventh ed., 2004, pp. 217-281.
74. V. Krcmery, A.J. Barnes, Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance, J. Hosp. Infect. 50 (2002) 243-260.
75. R.A. Fromtling, Overview of medically important antifungal azole derivatives, Clin. Microbiol. Rev. 1 (1988) 187-217.
76. P.D. Patel, M.R. Patel, B. Kocsis, E. Kocsis, S.M. Graham, A.R. Warren, S.M. Nicholson, B. Billack, F.R. Fronczek, T.T. Talele, Design, synthesis and determination of antifungal activity of 5(6)-substituted benzotriazoles, Eur. J. Med. Chem. 45 (2010) 2214-2222.
77. Z. Rezaei, S. Khabnadideh, K. Pakshir, Z. Hossaini, F. Amiri, E. Assadpour, Design, synthesis, and antifungal activity of triazole and benzotriazole derivatives, Eur. J. Med. Chem. 44 (2009) 3064-3067.
78. Z. Rezaei, S. Khabnadideh, K. Zomorodian, K. Pakshir, G. Kashi, N. Sanagoei, S. Gholami, Design, synthesis and antifungal activity of some new imidazole and triazole derivatives, Arch. Pharm. 344 (2011) 658-665.
79. N.D. Gaikwad, S.V. Patil, V.D. Bobade, Synthesis and biological evaluation of some novel thiazole substituted benzotriazole derivatives, Bioorg. Med. Chem. Lett. 22 (2012) 3449-3454.
80. R. Saini, S. Chaturvedi, A.N. Kesari, S. Kushwaha, Synthesis of 2-(substituted)-5-(benzotriazomethyl)-1, 3, 4-oxadiazole for anti-fungal activity, Der Pharma Chem. 2 (2010) 297-302.
81. K.K. Prasad, M.P. Toraskar, V.M. Kulkarni, V.J. Kadam, Microwave assisted synthesis and antifungal evaluation of schiff bases of benzotriazolyl-4-amino-1, 2, 4-triazoles, Indian Drugs 45 (2008) 934-939.
82. D.K. Shukla, S.D. Srivastava, Synthesis of some new 5 [2-{(1, 2, 3-benzotriazole)-1-yl-methyl}-1-(4-substituted aryl-3-chloro-2-oxo azetidine)]-amino-1, 3, 4-thiadiazoles: antifungal and antibacterial agents, Ind. J. Chem. 47B (2008) 463-470.
83. S.D. Srivastava, T.R. Rawat, Synthesis of new benzotriazole derivatives: antimicrobial and anticonvulsant agents, Indian J. Chem. 38B (1999) 623-627.
84. H.S. Patel, K.K. Oza, Synthesis, characterization and antimicrobial activity of metal chelates of 5 [1(H)-Benzotriazole methylene]-8-quinolinol, E-J. Chem. 6 (2009) 371-376.
85. Neglected Tropical Diseases, Soil-transmitted Helminths, 2012. Factsheet 1.
86. S. Nakhare, S.C. Garg, Anthelmintic activity of the essential oil of artemisia pallens wall, Anc. Sci. Life 10 (1991) 185-186.
87. M.W. Baker, J. Crowley, T.I. Watkins, N.G. Clark, Carbamoylbenzotriazole anthelmintics, Patent US3852457A, 1973.
88. M.S. Sudhir, R. Venkata Nadh, Evaluation of in vitro anthelmintic activities of novel 1, 2, 3 e benzotriazole derivatives synthesized in ultrasonic and solvent free conditions, J. Pha. Res. 7 (2013) 47-52.
89. N.S. Pawar, D.S. Dalal, S.R. Shimpi, P.P. Mahulikar, Studies of antimicrobial activity of N-alkyl and N-acyl 2-(4-thiazolyl)-1H-benzimidazoles, Eur. J. Pharm. Sci. 21 (2004) 115-118.
90. 2010/2011 Tuberculosis Global Facts, World Health Organization, 2010.
91. Global Tuberculosis Report, World Health Organization, Geneva, 2013.
92. Global Tuberculosis Control, World Health Organization, Geneva, 2011.
93. Report N4, Anti-tuberculosis Drug Resistance in the World, World Health Organization, Geneva, 2008.
94. TB/HIV Facts 2009, World Health Organization, Geneva, 2009.
95. M.S. Sanchez, J.O. Lloyd-Smith, W.M. Getz, Monitoring linked epidemics: the case of tuberculosis and HIV, PloS One 5 (2010) e8796.
96. P.L. Collins, B.S. Graham, Viral and host factors in human respiratory syncytial virus pathogenesis, J. Virol. 82 (2008) 2040-2055.
97. J.C. Garcia-Monco, Tuberculosis, in: Handbook of Clinical Neurology, vol. 121, 2014, pp. 1485-1499.
98. Treatment of Tuberculosis: Guidelines, World Health Organization, Geneva, 2009.
99. A. Singh, Fluoroquinolones should not be the first-line antibiotics to treat community-acquired pneumonia in areas of tuberculosis endemicity, Clin. Infect. Dis. 45 (2007) 134-135.
100. G.B. Migliori, C. Lange, E. Girardi, R. Centis, G. Besozzi, K. Kliiman, L.R. Codecasa, A. Spanevello, D.M. Cirillo, S.T.S. Group, Fluoroquinolones: are they essential to treat multidrug-resistant tuberculosis? Eur. Respir. J. 31 (2008) 904-905.
101. K. Manna, Y.K. Agrawal, Design, synthesis, and antitubercular evaluation of novel series of 3-benzofuran-5-aryl-1-pyrazolyl-pyridylmethanone and 3-benzofuran-5-aryl-1-pyrazolylcarbonyl-4-oxo-naphthyridin analogs, Eur. J. Med. Chem. 45 (2010) 3831-3839.
102. V.N. Telvekar, V.K. Bairwa, K. Satardekar, A. Bellubi, Novel 2-(2-(4-aryloxybenzylidene) hydrazinyl)benzothiazole derivatives as antitubercular agents, Bioorg. Med. Chem. Lett. 22 (2012) 649-652.
103. P.S. Mathapati, S.A. Durgad, K.C. Singh, S.D. Bhinge, Synthesis and antimycobacterial activity of benzimidazole derivatives, Indian Drugs 49 (2012) 17-25.
104. K. Kumar, D. Awasthi, S.Y. Lee, I. Zanardi, B. Ruzsicska, S. Knudson, P.J. Tonge, R.A. Slayden, I. Ojima, Novel trisubstituted benzimidazoles, targeting Mtb FtsZ, as a new class of antitubercular agents, J. Med. Chem. 54 (2011) 374-381.
105. P. Sanna, A. Carta, M.E. Nikookar, Synthesis and antitubercular activity of 3-aryl substituted-2 [1H(2H)benzotriazol-1(2)-yl]acrylonitriles, Eur. J. Med. Chem. 35 (2000) 535-543.
106. P. Sanna, A. Carta, L. Gherardini, M. Esmail, R. Nikookar, Synthesis and antimycobacterial activity of 3-aryl-, 3-cyclohexyl-and 3-heteroarylsubstituted-2-(1H(2H)-benzotriazol-1(2)-yl)prop-2-enenitriles, prop-2-enamides and propenoic acids. II, Farm. Sci. 57 (2002) 79-87.
107. A. Carta, P. Sanna, M. Palomba, L. Vargiu, M. La Colla, R. Loddo, Synthesis and antiproliferative activity of 3-aryl-2-(1H-benzotriazol-1-yl)acrylonitriles. Part III, Eur. J. Med. Chem. 37 (2002) 891-900.
108. A. Dubey, S.K. Srivastava, S.D. Srivastava, Conventional and microwave assisted synthesis of 2-oxo-4-substituted aryl-azetidine derivatives of benzotriazole: a new class of biological compounds, Bioorg. Med. Chem. Lett. 21 (2011) 569-573.
109. G.S. Singh, E. Mbukwa, T. Pheko, Synthesis and antimicrobial activity of new 2-azetidinones from N-(salicylidene)amines and 2-diazo-1, 2-diarylethanones, Arkivoc (2007) 80-90.
110. P.P. Dixit, V.J. Patil, P.S. Nair, S. Jain, N. Sinha, S.K. Arora, Synthesis of 1 [3-(4-benzotriazol-1/2-yl-3-fluoro-phenyl)-2-oxo-oxazolidin-5-ylmethyl]-3-substituted-thiourea derivatives as antituberculosis agents, Eur. J. Med. Chem. 41 (200) 423-428.
111. B.G. Mohamed, M.A. Hussein, A.A. Abdel-Alim, M. Hashem, Synthesis and antimicrobial activity of some new 1-alkyl-2-alkylthio-1, 2, 4-triazolobenzimidazole derivatives, Arch. Pharm. Res. 29 (2006) 26-33.
112. Z. Kazimierczuk, M. Andrzejewska, J. Kaustova, V. Klimesova, Synthesis and antimycobacterial activity of 2-substituted halogenobenzimidazoles, Eur. J. Med. Chem. 40 (2005) 203-208.
113. V. Klimesova, J. Koci, M. Pour, J. Stachel, K. Waisser, J. Kaustova, Synthesis and preliminary evaluation of benzimidazole derivatives as antimicrobial agents, Eur. J. Med. Chem. 37 (2002) 409-418.
114. R. Gasparova, M. Lacova, H.M. el-Shaaer, Z. Odlerova, Synthesis and antimycobacterial activity of some new 3-heterocyclic substituted chromones, Farm. Sci. 52 (1997) 251-253.
115. E. Augustynowicz-Kopec, Z. Zwolska, A. Orzeszko, Z. Kazimierczuk, Synthesis and antimycobacterial activity of selected nitrobenzyloxylated benzotriazoles, Acta Pol. Pharm. 65 (2008) 435-439.
116. A. Nuvole, P. Sanna, G. Paglietti, C. Juliano, S. Zanetti, P. Capucinelli, 1, 2, 3,-Triazolo [4, 5 f]-quinolines II. Preparation and microbial evaluation of 6-ethyl-6, 9-diydro-1(2)(3)H-triazolo [4, 5 f]-quinolin-9-one-8-carboxylic acids as anti-infectives of urinary tract, Farm. Sci. 44 (1989) 619-632.
117. A. Carta, M. Palomba, G. Paglietti, P. Molicotti, B. Paglietti, S. Cannas, S. Zanetti [1, 2, 3]Triazolo [4, 5-h]quinolones. A new class of potent antitubercular agents against multidrug resistant Mycobacterium tuberculosis strains, Bioorg. Med. Chem. Lett. 17 (2007) 4791-4794.
118. H.M. Blumberg, W.J. Burman, R.E. Chaisson, C.L. Daley, S.C. Etkind, L.N. Friedman, P. Fujiwara, M. Grzemska, P.C. Hopewell, M.D. Iseman, R.M. Jasmer, V. Koppaka, R.I. Menzies, R.J. O'Brien, R.R. Reves, L.B. Reichman, P.M. Simone, J.R. Starke, A.A. Vernon, C.f.D.C. American Thoracic Society, Prevention, S. The Infectious Diseases, American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis, Am. J. Resp. Crit. Care 167 (2003) 603-662.
119. K. Manika, I. Kioumis, The role of fluoroquinolones in the treatment of tuberculosis, Pneumon 4 (2008) 395-401.
120. E.R. Grimaldo, T.E. Tupasi, A.B. Rivera, M.I. Quelapio, R.C. Cardano, J.O. Derilo, V.A. Belen, Increased resistance to ciprofloxacin and ofloxacin in multidrugresistant mycobacterium tuberculosis isolates from patients seen at a tertiary hospital in the Philippines, J. Tuberc. Lung Dis. 5 (2001) 546-550.
121. C. Mugnaini, S. Pasquini, F. Corelli, The 4-quinolone-3-carboxylic acid motif as a multivalent scaffold in medicinal chemistry, Curr. Med. Chem. 16 (2009) 1746-1767.
122. C.M. Oliphant, G.M. Green, Quinolones: a comprehensive review, Am. Fam. Physician 65 (2002) 455-464.
123. A. Carta, S. Piras, M. Palomba, D. Jabes, P. Molicotti, S. Zanetti, Anti-mycobacterial activity of quinolones. Triazoloquinolones a new class of potent anti mycobacterial agents, Antiinfect. Agents Med. Chem. 7 (2008) 134-147.
124. L.E. Ziganshina, S.B. Squire, Fluoroquinolones for treating tuberculosis, Cochrane database Syst. Rev. (2008) CD004795.
125. V. Milata, Tricyclic azoloquinolines, Adv. Heterocycl. Chem. (2001) 189-268.
126. A. Carta, S. Zanetti, Triazolquinolonic Derivatives with Antimycobacterial Activity, 2008. WO2008107781 A3.
127. A. Carta, M. Palomba, I. Briguglio, P. Corona, S. Piras, D. Jabes, P. Guglierame, P. Molicotti, S. Zanetti, Synthesis and anti-mycobacterial activities of triazoloquinolones, Eur. J. Med. Chem. 46 (2011) 320-326.
128. I. Briguglio, S. Piras, P. Corona, M.A. Pirisi, D. Jabes, A. Carta, SAR and antimycobacterial activity of quinolones and triazoloquinolones. An update, Anti-Infective Agents 11 (2013) 75-89.
129. D. Tricarico, A. Mele, S. Calzolaro, G. Cannone, G.M. Camerino, M.M. Dinardo, R. Latorre, D. Conte Camerino, Emerging role of calcium-activated potassium channel in the regulation of cell viability following potassium ions challenge in HEK293 cells and pharmacological modulation, PloS one 8 (2013) e69551.
130. M. Holland, P.D. Langton, N.B. Standen, J.P. Boyle, Effects of the BKCa channel activator, NS1619, on rat cerebral artery smooth muscle, Br. J. Pharmacol. 117 (1996) 119-129.
131. B. Baragatti, G. Biagi, V. Calderone, I. Giorgi, O. Livi, E. Martinotti, V. Scartoni, Triazolyl-benzimidazolones and triazolyl-benzotriazoles: new potential potassium channel activators. II, Eur. J. Med. Chem. 35 (2000) 949-955.
132. G. Biagi, V. Calderone, I. Giorgi, O. Livi, V. Scartoni, B. Baragatti, E. Martinotti, Some structural changes on triazolyl-benzotriazoles and triazolylbenzimidazolones as potential potassium channel activators. III, Farm. Sci. 56 (2001) 841-849.
133. G. Biagi, I. Giorgi, O. Livi, V. Scartoni, P.L. Barili, V. Calderone, E. Martinotti, New 5-substituted-1-(2-hydroxybenzoyl)-benzotriazoles, potassium channel activators. IV, Farm. Sci. 56 (2001) 827-834.
134. A. Jemal, F. Bray, M.M. Center, J. Ferlay, E. Ward, D. Forman, Global cancer statistics, Cancer J. Clin. 61 (2011) 69-90.
135. Globocan, Cancer Fact Sheets, 2012. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx.
136. J. Ferlay, H.R. Shin, F. Bray, D. Forman, C. Mathers, D.M. Parkin, Globocan 2008: Cancer Incidence and Mortality Worldwide, 2010. IARC CancerBase No. 10.
137. E. Enger, F.C. Ross, D. Bailey, Concepts in Biology, 2007.
138. K. Lotfi-Jam, M. Carey, M. Jefford, P. Schofield, C. Charleson, S. Aranda, Nonpharmacologic strategies for managing common chemotherapy adverse effects: a Systematic review, J. Clin. Oncol. 26 (2008) 5618-5629.
139. A.A. El Rashedy, H.Y. Aboul-Enein, Benzimidazole derivatives as potential anticancer agents, Mini Rev. Med. Chem. 13 (2013) 399-407.
140. A. Husain, M. Rashid, R. Mishra, S. Parveen, D.S. Shin, D. Kumar, Benzimidazole bearing oxadiazole and triazolo-thiadiazoles nucleus: design and synthesis as anticancer agents, Bioorg. Med. Chem. Lett. 22 (2012) 5438-5444.
141. J. Chen, S. Ahn, J. Wang, Y. Lu, J.T. Dalton, D.D. Miller, W. Li, Discovery of novel 2-aryl-4-benzoyl-imidazole (ABI-III) analogues targeting tubulin polymerization as antiproliferative agents, J. Med. Chem. 55 (2012) 7285-7289.
142. A. Carta, M. Palomba, G. Boatto, B. Busonera, M. Murreddu, R. Loddo, Synthesis and antiproliferative activity of 3-aryl-2 [1H(2H)-benzotriazol-1(2)-yl]acrylonitriles variously substituted: Part 4, Farm. Sci. 59 (2004) 637-644.
143. S. Zanias, G.S. Papaefstathiou, C.P. Raptopoulou, K.T. Papazisis, V. Vala, D. Zambouli, A.H. Kortsaris, D.A. Kyriakidis, T.F. Zafiropoulos, Synthesis, structure, and antiproliferative activity of three Gallium(III) azole complexes, Bioinorg. Chem. Appl. (2010). Article ID 168030.
144. T. Zhan, H. Lou, Synthesis of azole nucleoside analogues of D-pinitol as potential antitumor agents, Carbohydr. Res. 342 (2007) 865-869.
145. J. Saunders, J.M. Cameron, Recent development in the design of antiviral agents, Med. Res. Rev. 15 (1995) 497-531.
146. L. Agrofoglio, E. Suhasa, A. Faresea, R. Condoma, S.R. Challandb, R.A. Earlc, R. Guedja, Synthesis of carbocyclic nucleosides, Tetrahedron 50 (1994) 10611-10670.
147. M.T. Crimmins, New developments in the enantioselective synthesis of cyclopentyl carbocyclic nucleosides, Tetrahedron 54 (1998) 9229-9272.
148. Y.A. Al-Soud, N.A. Al-Masoudi, R. Ferwanah Ael, Synthesis and properties of new substituted 1, 2, 4-triazoles: potential antitumor agents, Bioorg. Med. Chem. 11 (2003) 1701-1708.
149. C. Lamazzi, S. Leonce, B. Pfeiffer, P. Renard, G. Guillaumet, C.W. Rees, T. Besson, Expeditious synthesis and cytotoxic activity of new cyanoindolo [3, 2-c]quinolines and benzimidazo [1, 2-c]quinazolines, Bioorg. Med. Chem. Lett. 10 (2000) 2183-2185.
150. L. He, H.X. Chang, T.C. Chou, N. Savaraj, C.C. Cheng, Design of antineoplastic agents based on the '2-phenylnaphthalene-type' structural pattern e synthesis and biological activity studies of 11H-indolo [3.2-c]quinoline derivatives, Eur. J. Med. Chem. 38 (2003) 101-107.
151. A. Beauchard, H. Chabane, S. Sinbandhit, P. Guenot, V. Thi-ery, T. Besson, synthesis of original thiazoloindolo [3, 2-c]quinoline and novel 8-Nsubstituted-11H-indolo [3, 2c]quinoline derivatives from benzotriazoles. Part I, Tetrahedron 62 (2006) 1895-1903.
152. A. Beauchard, H. Chabanea, S. Sinbandhitb, P. Guenotb, V. Thi-erya, T. Bessona, Synthesis of original thiazoloindolo [3, 2-c]quinoline and novel 8-Nsubstituted-11H-indolo [3, 2-c]quinoline derivatives from benzotriazoles. Part I, Tetrahedron 62 (2006) 1895-1903.
153. J. Wan, C.L. Li, X.M. Li, S.S. Zhang, Synthesis, structure and biological activities of 2-(1H-1, 2, 3-benzotriazol-1-yl)-1-(4-methylphenyl)-2-(1H-1, 2, 4-triazol-1-yl)-1-ethanone, Chem. Res. Chin. Univ. 22 (2006) 465-467.
154. S.S. Zhang, J. Wan, X.M. Li, C.L. Li, L.Z. Xu, Syntheses, structure and biological activities of 2-(1Hbenzo [1, 2, 3]triazole-1-y1)-1-(3-methyl-4-bromobipheny1)-2-(1H-1, 2, 4-triazole-1-y1)ethanon, Chem. Res. Chin. Univ. 23 (2007) 120-122.
155. S.S. Zhang, J. Wan, C.L. Li, M. Li, B. Qu, Syntheses and biological activities of novel triazole compounds, J. Heterocycl. Chem. 44 (2007) 75-78.
156. S.S. Zhang, H.Q. Zhang, D. Li, L.H. Sun, C.P. Ma, W. Wang, J. Wan, B. Qu, A novel benzotriazole derivative inhibits proliferation of human hepatocarcinoma cells by increasing oxidative stress concomitant mitochondrial damage, Eur. J. Pharmacol. 584 (2008) 144-152.
157. R. Abonia, B. Insuastya, J. Quirogaa, M. Noguerasb, H. Meierc, Use of b-(N, Ndialkylamino) propiophenones in the synthesis of nitrogenated heterocyclic compounds, Mini Rev. Org. Chem. 1 (2004) 387-402.
158. K.M. Kasiotis, S.A. Haroutounian, 2-Pyridin-2-yl-1H-indole derivatives: synthesis, estrogen receptor binding affinity, and photophysical properties, Bioorg. Chem. 34 (2006) 1-14.
159. J. Wan, X. Yan, C. Cuiping Ma, S. Bi, H.L. Zhu, Synthesis, structure characterization, and biological evaluation of some new 1, 2, 3-benzotriazole derivatives, Med. Chem. Res. 19 (2010) 970-983.
160. B.R. Hearn, S.J. Shaw, D.C. Myles, Microtubule targeting agents, in: J.B. Taylor, D.J. Triggle (Eds.), Comprehensive Medicinal Chemistry II, 2007, pp. 81-110.
161. N. Mahindroo, J.P. Liou, J.Y. Chang, H.P. Hsieh, Antitubulin agents for treatment of Cancer-a medicinal chemistry update, Expert Opin. Ther. Pat. 16 (2006) 647-691.
162. S.K. Tahir, P. Kovar, S.H. Rosenberg, S.C. Ng, Rapid colchicine competitionbinding scintillation proximity assay using biotin-labeled tubulin, Bio-Techniques 29 (2000) 156-160.
163. L.A. Howell, A. Howman, M.A. O'Connell, A. Mueller, M. Searcey, Synthesis and evaluation of 9-aminoacridines derived from benzyne click chemistry, Bioorg. Med. Chem. Lett. 19 (2009) 5880-5883.
164. D.W. Litchfield, Protein kinase CK2: structure, regulation and role in cellular decisions of life and death, Biochem. J. 369 (2003) 1-15.
165. K. Ahmed, D.A. Gerber, C. Cochet, Joining the cell survival squad: an emerging role for protein kinase CK2, Trends Cell. Biol. 12 (2002) 226-230.
166. A. Ghavidel, M.C. Schultz, TATA binding protein-associated CK2 transduces DNA damage signals to the RNA polymerase III transcriptional machinery, Cell 106 (2001) 575-584.
167. G. Burnett, E.P. Kennedy, The enzymatic phosphorylation of proteins, J. Biol. Chem. 211 (1954) 969-980.
168. C.V. Glover, A filamentous form of Drosophila casein kinase II, J. Biol. Chem. 261 (1986) 14349-14354.
169. E. Valero, S. De Bonis, O. Filhol, R.H. Wade, J. Langowski, E.M. Chambaz, C. Cochet, Quaternary structure of casein kinase 2. Characterization of multiple oligomeric states and relation with its catalytic activity, J. Biol. Chem. 270 (1995) 8345-8352.
170. W. Pyerin, K. Ackermann, Transcriptional coordination of the genes encoding catalytic (CK2alpha) and regulatory (CK2beta) subunits of human protein kinase CK2, Mol. Cell. Biochem. 227 (2001) 45-57.
171. W. Pyerin, K. Ackermann, The genes encoding human protein kinase CK2 and their functional links, Prog. Nucleic Acid. Res. Mol. Biol. 74 (2003) 239-273.
172. U. Wirkner, H. Voss, W. Ansorge, W. Pyerin, Genomic organization and promoter identification of the human protein kinase CK2 catalytic subunit alpha (CSNK2-1), Genomics 48 (1998) 71-78.
173. V. Martel, O. Filhol, A. Nueda, D. Gerber, M.J. Benitez, C. Cochet, Visualization and molecular analysis of nuclear import of protein kinase CK2 subunits in living cells, Mol. Cell. Biochem. 227 (2001) 81-90.
174. V. Martel, O. Filhol, A. Nueda, C. Cochet, Dynamic localization/association of protein kinase CK2 subunits in living cells: a role in its cellular regulation? Ann. N. Y. Acad. Sci. 973 (2002) 272-277.
175. F. Meggio, D. Shugar, L.A. Pinna, Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1, Eur. J. Biochem. 187 (1990) 89-94.
176. A.C. Bibby, D.W. Litchfield, The multiple personalities of the regulatory subunit of protein kinase CK2: CK2 dependent and CK2 independent roles reveal a secret identity for CK2beta, Int. J. Biol. Sci. 1 (2005) 67-79.
177. L. Volodina Iu, A.A. Shtil, [Casein kinase 2, the versatile regulator of cell survival], Mol. Biol. Mosk. 46 (2012) 423-433.
178. L.A. Pinna, F. Meggio, Protein kinase CK2 ("casein kinase-2") and its implication in cell division and proliferation, Prog. Cell. Cycle Res. 3 (1997) 77-97.
179. D.C. Seldin, P. Leder, Casein kinase II alpha transgene-induced murine lymphoma: relation to theileriosis in cattle, Science 267 (1995) 894-897.
180. R.A. Faust, M. Gapany, P. Tristani, A. Davis, G.L. Adams, K. Ahmed, Elevated protein kinase CK2 activity in chromatin of head and neck tumors: association with malignant transformation, Cancer Lett. 101 (1996) 31-35.
181. P. Channavajhala, D.C. Seldin, Functional interaction of protein kinase CK2 and c-Myc in lymphomagenesis, Oncogene 21 (2002) 5280-5288.
182. B. Guerra, O.G. Issinger, Protein kinase CK2 and its role in cellular proliferation, development and pathology, Electrophoresis 20 (1999) 391-408.
183. S. Sarno, H. Reddy, F. Meggio, M. Ruzzene, S.P. Davies, A. Donella-Deana, D. Shugar, L.A. Pinna, Selectivity of 4, 5, 6, 7-tetrabromobenzotriazole, an ATP site-directed inhibitor of protein kinase CK2 ('casein kinase-2'), FEBS Lett. 496 (2001) 44-48.
184. M. Lasa, O. Marin, L.A. Pinna, Rat liver Golgi apparatus contains a protein kinase similar to the casein kinase of lactating mammary gland, Eur. J. Biochem. 243 (1997) 719-725.
185. P. Zien, M. Bretner, K. Zastapio, R. Szyszka, D. Shugar, Selectivity of 4, 5, 6, 7-tetrabromobenzimidazole as an ATP-competitive potent inhibitor of protein kinase CK2 from various sources, Biochem. Biophys. Res. Commun. 306 (2003) 129-133.
186. P. Zien, O. Abramczyk, K. Domanska, M. Bretner, R. Szyszka, TBBz but not TBBt discriminates between two molecular forms of CK2 in vivo and its implications, Biochem. Biophys. Res. Commun. 312 (2003) 623-628.
187. P. Zien, J.S. Duncan, J. Skierski, M. Bretner, D.W. Litchfield, D. Shugar, Tetrabromobenzotriazole (TBBt) and tetrabromobenzimidazole (TBBz) as selective inhibitors of protein kinase CK2: evaluation of their effects on cells and different molecular forms of human CK2, Biochim. Biophys. Acta 1754 (2005) 271-280.
188. R. Battistutta, M. Mazzorana, L. Cendron, A. Bortolato, S. Sarno, Z. Kazimierczuk, G. Zanotti, S. Moro, L.A. Pinna, The ATP-binding site of protein kinase CK2 holds a positive electrostatic area and conserved water molecules, Chembiochem 8 (2007) 1804-1809.
189. R. Battistutta, E. De Moliner, S. Sarno, G. Zanotti, L.A. Pinna, Structural features underlying selective inhibition of protein kinase CK2 by ATP sitedirected tetrabromo-2-benzotriazole, Protein Sci. 10 (2001) 2200-2206.
190. N.G. Brink, K. Folkers, Vitamin B12. VI. 5, 6-Dimethylbenzimidazole, a degradation product of vitamin B12, J. Am. Chem. Soc. 71 (1949) 2951.
191. N.G. Brink, F.W. Holly, C.H. Shunk, E.W. Peel, J.J. Cahill, K. Folkers, Vitamin B12. IX. 1-a-ribofuranosido-5, 6-dimethylbenzimidazole, a degradation product of vitamin B12, J. Am. Chem. Soc. 72 (1950) 1866.
192. R. Zandomeni, R. Weinmann, Inhibitory effect of 5, 6-dichloro-1-beta-Dribofuranosylbenzimidazole on a protein kinase, J. Biol. Chem. 259 (1984) 14804-14811.
193. R. Zandomeni, M.C. Zandomeni, D. Shugar, R. Weinmann, Casein kinase type II is involved in the inhibition by 5, 6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription, J. Biol. Chem. 261 (1986) 3414-3419.
194. G. Dobrowolska, G. Muszynska, D. Shugar, Benzimidazole nucleoside analogues as inhibitors of plant (maize seedling) casein kinases, Biochim. Biophys. Acta 1080 (1991) 221-226.
195. R. Wasik, P. Winska, J. Poznanski, D. Shugar, Synthesis and physico-chemical properties in aqueous medium of all possible isomeric bromo analogues of benzo-1H-triazole, potential inhibitors of protein kinases, J. Phys. Chem. B 116 (2012) 7259-7268.
196. M. Bretner, A. Najda-Bernatowicz, M. Lebska, G. Muszynska, A. Kilanowicz, A. Sapota, New inhibitors of protein kinase CK2, analogues of benzimidazole and benzotriazole, Mol. Cell. Biochem. 316 (2008) 87-89.
197. A. Orzeszko, W. Lasek, T. Switaj, M. Stoksik, B. Kaminska, Tumor necrosis factor-alpha production-regulating activity of phthalimide derivatives in genetically modified murine melanoma cells B78-1, Farm. Sci. 58 (2003) 371-376.
198. M.F. Brana, G. Dominguez, B. Saez, C. Romerdahl, S. Robinson, T. Barlozzari, Synthesis of antitumor dendritic imides, Bioorg. Med. Chem. Lett. 11 (2001) 3027-3029.
199. A. Najda-Bernatowicz, M. Lebska, A. Orzeszko, K. Kopanska, E. Krzywinska, G. Muszynska, M. Bretner, Synthesis of new analogs of benzotriazole, benzimidazole and phthalimideepotential inhibitors of human protein kinase CK2, Bioorg. Med. Chem. 17 (2009) 1573-1578.
200. M.A. Pagano, M. Andrzejewska, M. Ruzzene, S. Sarno, L. Cesaro, J. Bain, M. Elliott, F. Meggio, Z. Kazimierczuk, L.A. Pinna, Optimization of protein kinase CK2 inhibitors derived from 4, 5, 6, 7-tetrabromobenzimidazole, J. Med. Chem. 47 (2004) 6239-6247.
201. F. Pierre, P.C. Chua, S.E. O'Brien, A. Siddiqui-Jain, P. Bourbon, M. Haddach, J. Michaux, J. Nagasawa, M.K. Schwaebe, E. Stefan, A. Vialettes, J.P. Whitten, T.K. Chen, L. Darjania, R. Stansfield, K. Anderes, J. Bliesath, D. Drygin, C. Ho, M. Omori, C. Proffitt, N. Streiner, K. Trent, W.G. Rice, D.M. Ryckman, Discovery and SAR of 5-(3-chlorophenylamino)benzo [c] [2, 6]naphthyridine-8-carboxylic acid (CX-4945), the first clinical stage inhibitor of protein kinase CK2 for the treatment of cancer, J. Med. Chem. 54 (2011) 635-654.
202. Z. Nie, C. Perretta, P. Erickson, S. Margosiak, R. Almassy, J. Lu, A. Averill, K.M. Yager, S. Chu, Structure-based design, synthesis, and study of pyrazolo [1, 5-a] [1, 3, 5]triazine derivatives as potent inhibitors of protein kinase CK2, Bioorg. Med. Chem. Lett. 17 (2007) 4191-4195.
203. M. Makowska, E. Lukowska-Chojnacka, P. Winska, A. Kus, A. Bilinska-Chomik, M. Bretner, Design and synthesis of CK2 inhibitors, Mol. Cell. Biochem. 356 (2011) 91-96.
204. R. Swider, M. Maslyk, S. Martin-Santamaria, A. Ramos, B. de Pascual-Teresa, Multisite-directed inhibitors of protein kinase CK2: new challenges, Mol. Cell. Biochem. 356 (2011) 117-119.
205. D. Lavogina, E. Enkvist, A. Uri, Bisubstrate inhibitors of protein kinases: from principle to practical applications, Chem. Med. Chem. 5 (2010) 23-34.
206. A.M. Wawro, M. Wielechowska, M. Bretner, Synthesis of new optically pure tetrabromobenzotriazole derivatives via lipase-catalyzed transesterification, J. Mol. Catal. B: Enzym. 87 (2013) 44-50.
207. S. Wasson, M. Kerzic, J. Hall, M. Cates, J. Wasson, Characterization of metal benzotriazoles and related polymers, Int. Centre Diffr. Data 42 (2000) 555-561.
208. B.K. Keppler, Metal complexes in cancer chemotherapy, Appl. Organomet. Chem. 8 (1994).
209. F. Saczewski, E. Dziemidowicz-Borys, P.J. Bednarski, M. Gdaniec, Synthesis, crystal structure, cytotoxic and superoxide dismutase activities of copper(II) complexes of N-(4, 5-dihydroimidazol-2-yl)azoles, Arch. Pharm. 340 (2007) 333-338.
210. L.W. Oberley, G.R. Buettner, Role of superoxide dismutase in cancer: a review, Cancer Res. 39 (1979) 1141-1149.
211. M. Grunstein, Histone acetylation in chromatin structure and transcription, Nature 389 (1997) 349-352.
212. J.R. Davie, Covalent modifications of histones: expression from chromatin templates, Curr. Opin. Genet. Dev. 8 (1998) 173-178.
213. A. Mai, S. Massa, R. Ragno, I. Cerbara, F. Jesacher, P. Loidl, G. Brosch, 3-(4-Aroyl-1-methyl-1H-2-pyrrolyl)-N-hydroxy-2-alkylamides as a new class of synthetic histone deacetylase inhibitors. 1. Design, synthesis, biological evaluation, and binding mode studies performed through three different docking procedures, J. Med. Chem. 46 (2003) 512-524.
214. R.W. Johnstone, Histone-deacetylase inhibitors: novel drugs for the treatment of cancer, Nat. Rev. Drug. Discov. 1 (2002) 287-299.
215. M. Dokmanovic, C. Clarke, P.A. Marks, Histone deacetylase inhibitors: overview and perspectives, Mol. Cancer Res. 5 (2007) 981-989.
216. D.C. Drummond, C.O. Noble, D.B. Kirpotin, Z. Guo, G.K. Scott, C.C. Benz, Clinical development of histone deacetylase inhibitors as anticancer agents, Annu. Rev. Pharmacol. Toxicol. 45 (2005) 495-528.
217. J. Fu, Y. Yang, X.W. Zhang, W.J. Mao, Z.M. Zhang, H.L. Zhu, Discovery of 1Hbenzo [d] [1, 2, 3]triazol-1-yl 3, 4, 5-trimethoxybenzoate as a potential antiproliferative agent by inhibiting histone deacetylase, Bioorg. Med. Chem. 18 (2010) 8457-8462.
218. R. Huey, G.M. Morris, A.J. Olson, D.S. Goodsell, A semiempirical free energy force field with charge-based desolvation, J. Comput. Chem. 28 (2007) 1145-1152.
219. X. Li, J. Fu, W. Shi, Y. Luo, X. Zhang, H. Zhu, H. Yu, 3D-QSAR and molecular docking studies on benzotriazoles as antiproliferative agents and histone deacetylase inhibitors, Bull. Korean Chem. Soc. 34 (2013) 2387-2393.
220. T.M. Willson, P.J. Brown, D.D. Sternbach, B.R. Henke, The PPARs: from orphan receptors to drug discovery, J. Med. Chem. 43 (2000) 527-550.
221. V.J. Ram, Therapeutic role of peroxisome proliferator-activated receptors in obesity, diabetes and inflammation, Progress in drug research. Fortschritte der Arzneimittelforschung, Prog. Drug. Res. 60 (2003) 93-132.
222. K.L. Gearing, M. Gottlicher, M. Teboul, E. Widmark, J.A. Gustafsson, Interaction of the peroxisome-proliferator-activated receptor and retinoid X receptor, Proc. Nati. Acad. Sci. (1993) 1440-1444.
223. M. Bortolini, M.B. Wright, M. Bopst, B. Balas, Examining the safety of PPAR agonists-current trends and future prospects, Expert Opin. Drug Saf. 12 (2013) 65-79.
224. B.R. Henke, Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes, J. Med. Chem. 47 (2004) 4118-4127.
225. P. Sauerberg, P.S. Bury, J.P. Mogensen, H.J. Deussen, I. Pettersson, J. Fleckner, J. Nehlin, K.S. Frederiksen, T. Albrektsen, N. Din, L.A. Svensson, L. Ynddal, E.M. Wulff, L. Jeppesen, Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo, J. Med. Chem. 46 (2003) 4883-4894.
226. A. Sparatore, C. Godio, E. Perrino, S. Romeo, B. Staels, J.C. Fruchart, M. Crestani [4-(2H-1, 2, 3-benzotriazol-2-yl)phenoxy]alkanoic acids as agonists of peroxisome proliferator-activated receptors (PPARs), Chem. Biodivers. 3 (2006) 385-395.
227. A. Sparatore, F. Sparatore, Synthesis and preliminary pharmacological investigation of some 2 [4-(dialkylaminoalkoxy)phenyl]benzotriazoles and their N-oxides, Farm. Sci. 53 (1998) 02-112.
228. A.A. Santilli, A.C. Scotese, R.M. Tomarelli, A potent antihypercholesterolemic agent: (4-chloro-6-(2, 3-xylidino)-2-pyrimidinylthio) acetic acid (Wy-14643), Experientia 30 (1974) 1110-1111.
229. S. Kato, Role of serotonin 5-HT(3) receptors in intestinal inflammation, Biol. Pharm. Bull. 36 (2013) 1406-1409.
230. E. Zifa, G. Fillion, 5-Hydroxytryptamine receptors, Pharmacol. Rev. 44 (1992) 401-458.
231. P. Masek, A.C. Keene, Dopamine: on the threshold of sleep, Curr. Biol. 22 (2012) R949-R951.
232. J. Zohar, T.R. Insel, R.C. Zohar-Kadouch, J.L. Hill, D.L. Murphy, Serotonergic responsivity in obsessive-compulsive disorder. Effects of chronic clomipramine treatment, Arch. Gen. Psychiatry 45 (1988) 167-172.
233. E. Shin, J. Garcia, C. Winkler, A. Bjorklund, M. Carta, Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease, Neurobiol. Dis. 47 (2012) 393-406.
234. R.A. Urbanek, H. Xiong, Y. Wu, W. Blackwell, G. Steelman, J. Rosamond, S.S. Wesolowski, J.B. Campbell, M. Zhang, B. Brockel, D.V. Widzowski, Synthesis and SAR of aminothiazole fused benzazepines as selective dopamine D(2) partial agonists, Bioorg. Med. Chem. Lett. 23 (2013) 543-547.
235. R. Condray, J.K. Yao, Cognition, dopamine and bioactive lipids in schizophrenia, Front. Biosci. Sch. Ed. 3 (2011) 298-330.
236. G. Caliendo, R. Di Carlo, R. Meli, E. Perissutti, V. Santagada, C. Silipo, A. Vittoria, Synthesis and trazodone-like pharmacological profiles of 1-and 2 [3 [4-(x)-1-piperazinyl]-propyl]-benzotriazoles, Eur. J. Med. Chem. 28 (1993) 969-974.
237. G. Caliendo, R. Di Carlo, G. Greco, R. Meli, E. Novellino, E. Perissutti, V. Santagada, Synthesis and biological activity of benzotriazole derivatives structurally related to trazadone, Eur. J. Med. Chem. 30 (1995) 77-84.
238. G. Caliendo, G. Greco, P. Grieco, E. Novellino, E. Perissutti, V. Santagada, D. Barbarulo, E. Esposito, A. De Blasi, Structureeaffinity relationship studies on benzotriazole derivatives binding to 5-HT receptor subtypes, Eur. J. Med. Chem. 31 (1996) 207-213.
239. A. Sparatore, M. Goegan, A. Cagnotto, F. Sparatore, 2 [4[3-(4-aryl/heteroaryl-1-piperazinyl)propoxy]phenyl]-2H-benzotriazoles and their N-oxides as ligands for serotonin and dopamine receptors, Farm. Sci. 54 (1999) 402-410.
240. R.A. Glennon, R. Westkaemper, P. Bartyzel, Medicinal chemistry of serotonergic agents, in: S. Peroutka (Ed.), Serotonin Receptor Subtypes, Wiley-Liss, NY, 1991, pp. 19-64.
241. M.J. Mokrosz, M.H. Paluchowska, S. Charakchieva-Minol, A. Bien, Structureactivity relationship studies of CNS agents, Part 32: effect of structural modifications in 1-arylpiperazine derivatives on alpha(1)-adrenoreceptor affinity, Arch. Pharm. 330 (1997) 177-180.
242. A. Sparatore, F. Sparatore, 2-{4-[u-[4-(2-Methoxyphenyl)-1-piperazinyl] alkoxy]phenyl}-2H-benzotriazoles and their N-Oxides as Ligands for some 5-Hydroxytryptamine, Dopamine and Adrenergic Receptor Subtypes, Pharm. Pharmacol. Commun. 6 (2000) 421-425.
243. J.L. Mokrosz, M.H. Paluchowska, E. Chojnacka-Wojcik, M. Filip, S. Charakchieva-Minol, A. Deren-Wesolek, M.J. Mokrosz, Structure-activity relationship studies of central nervous system agents. 13. 4 [3-(Benzotriazol-1-yl)propyl]-1-(2-methoxyphenyl)piperazine, a new putative 5-HT1A receptor antagonist, and its analogs, J. Med. Chem. 37 (1994) 2754-2760.
244. M.H. Paluchowska, A. Klodzinska, E. Tatarczynska, A. Szaro, E. Chojnacka-Wojcik, Effect of linking bridge modifications on the 5-HT1A receptor activity of some 4-(omega-benzotriazol-1-yl)alkyl-1-(2-methoxy-phenyl)piperazines, Pol. J. Pharmacol. 50 (1998) 341-347.
245. A. Boido, C.C. Boido, F. Sparatore, Synthesis and pharmacological evaluation of aryl/heteroaryl piperazinyl alkyl benzotriazoles as ligands for some serotonin and dopamine receptor subtypes, Farm. Sci. 56 (2001) 263-275.
246. V. Sukalovic, D. Andric, G. Roglic, S. Kostic-Rajacic, A. Schrattenholz, V. Soskic, Synthesis, dopamine D2 receptor binding studies and docking analysis of 5 [3-(4-arylpiperazin-1-yl)propyl]-1H-benzimidazole, 5 [2-(4-arylpiperazin-1-yl)ethoxy]-1H-benzimidazole and their analogs, Eur. J. Med. Chem. 40 (2005) 481-493.
247. F. Pagani, F. Sparatore, Benzotriazolyl-alkyl-benzimidazoles and their dialkyl-aminoalkyl derivatives, Boll. Chim. Farm. 104 (1965) 427-431.
248. P. Preziosi, P. Manca, G. Paglietti, Choleretic activity of benzotriazolylalkanoic acids, Farm. Sci. 20 (1965) 238-247.
249. G. Paglietti, F. Sparatore, Preparation of variously substituted betabenzotriazolylbutyric acids with potential choleretic activity, Farm. Sci. 27 (1972) 380-396.
250. G. Paglietti, F. Sparatore, Preparation of beta-benzimidazolyl-and indazolylbutyric acids as potential choleretic agents, Farm. Sci. 27 (1972) 471-479.
251. A. Boido, I. Vazzana, F. Mattioli, F. Sparatore, Antiinflammatory and antinociceptive activities of some benzotriazolylalkanoic acids, Farm. Sci. 58 (2003) 33-44.
252. G. Semple, P.J. Skinner, M.C. Cherrier, P.J. Webb, C.R. Sage, S.Y. Tamura, R. Chen, J.G. Richman, D.T. Connolly, 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of he human orphan G-protein-coupled receptor GPR109b, J. Med. Chem. 49 (2006) 1227-1230.
253. W. Soudijn, I. van Wijngaarden, A.P. Ijzerman, Nicotinic acid receptor subtypes and their ligands, Med. Res. Rev. 27 (2007) 417-433.
254. F. Sparatore, A. Boido, B. Cappello, V. Diurno, M.T. Mazza, E. Piscopo, I. Vazzana, 4'-Benzotriazol-2-yl)-phenylalkanoic and-phenoxyalkanoic acids and corresponding N-oxides as potential anti-inflammatory agents, Boll. Soc. Ital. Biol. Sper. 57 (1981) 871-876.
255. A. Boido, I. Vazzana, F. Sparatore, B. Cappello, V. Diurno, C. Matera, R. Marrazzo, S. Russo, M.L. Cenicola, E. Marmo, Preparation and pharmacologic activity of N-oxides of 4'-(benzotriazol-2-yl-phenylalkanoic and-phenoxyalkanoic acids, Farm. Sci. 44 (1989) 257-277.
256. N.P. Buu-Houi, P. Jacquignon, J.P. Hoeffinger, The pharmacological activity of some 2-substituited benzimidazoles, Arzneimittelforschung 13 (1963) 865-867.
257. A. Boido, I. Vazzana, F. Sparatore, M.L. Cenicola, D. Donnoli, E. Marmo, Preparation and pharmacological activity of some 1-lupinylbenzimidazoles and 1-lupinylbenzotriazoles, Farm. Sci. 46 (1991) 775-788.
258. I. Vazzana, A. Boido, F. Sparatore, R. Di Carlo, G.M. Raso, M. Pacilio, Preparation and local anaesthetic activity of N [2-(tert-amino)ethyl]-and N-(lupinyl)-benzotriazol-1/2-ylacetamides, Farm. Sci. 52 (1997) 131-139.
259. A. Rajasekaran, K.A. Rajagopal, Synthesis of some novel triazole derivatives as anti-nociceptive and anti-inflammatory agents, Acta Pharm. 59 (2009) 355-364.
260. A. Rajasekaran, S. Murugesan, K. AnandaRajagopal, Antibacterial, antifungal and anticonvulsant evaluation of novel newly synthesized 1 [2-(1H-Tetrazol-5-yl)ethyl]-I h-benzo [d] [1, 2, 3]triazoles, Arch. Pharm. Res. 29 (2006) 535-540.
261. L. Santana, M. Teijeira, E. Uriarte, C. Teran, B. Linares, R. Villar, R. Laguna, E. Cano, AM1 theoretical study, synthesis and biological evaluation of some benzofuran analogues of anti-inflammatory arylalkanoic acids, Eur. J. Pharm. Sci. 7 (1999) 161-166.
262. K.M. Dawood, H. Abdel-Gawad, E.A. Rageb, M. Ellithey, H.A. Mohamed, Synthesis, anticonvulsant, and anti-inflammatory evaluation of some new benzotriazole and benzofuran-based heterocycles, Bioorg. Med. Chem. 14 (2006) 3672-3680.
263. M. Bretner, A. Baier, K. Kopanska, A. Najda, A. Schoof, M. Reinholz, A. Lipniacki, A. Piasek, T. Kulikowski, P. Borowski, Synthesis and biological activity of 1H-benzotriazole and 1H-benzimidazole analogues-inhibitors of the NTpase/helicase of HCV and of some related Flaviviridae, Antivir. Chem. Chemother. 16 (2005) 315-326.
264. I. Briguglio, S. Piras, P. Corona, A. Carta, Inhibition of RNA helicases of ssRNA\+ virus belonging to flaviviridae, coronaviridae and picornaviridae families, Int. J. Med. Chem. 2011 (2011).
265. Nonpolio enterovirus and human parechovirus surveillance e United States, 2006-2008, Morb. Mortal. Wkly. Rep. 59 (2010) 1577-1580.
266. P.H. Hayashi, A.M. Di Bisceglie, The progression of hepatitis B-and C-infections to chronic liver disease and hepatocellular carcinoma: presentation, diagnosis, screening, prevention, and treatment of hepatocellular carcinoma, Med. Clin. North Am. 89 (2005) 345-369.
267. J. Paeshuyse, I. Vliegen, L. Coelmont, P. Leyssen, O. Tabarrini, P. Herdewijn, H. Mittendorfer, J. Easmon, V. Cecchetti, R. Bartenschlager, G. Puerstinger, J. Neyts, Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors, Antimicrob. Agents Chemother. 52 (2008) 3433-3437.
268. M. Bretner, A. Najda, R. Podwinska, A. Baier, K. Paruch, A. Lipniacki, A. Piasek, P. Borowski, T. Kulikowski, Inhibitors of the NTPase/helicases of hepatitis C and related Flaviviridae viruses, Acta Pol. Pharm. 61 (Suppl. l) (2004) 26-28.
269. D.J. Porter, A kinetic analysis of the oligonucleotide-modulated ATPase activity of the helicase domain of the NS3 protein from hepatitis C virus. The first cycle of interaction of ATP with the enzyme is unique, J. Biol. Chem. 273 (1998) 14247-14253.
270. A. Carta, G. Loriga, S. Piras, G. Paglietti, M. Ferrone, M. Fermeglia, S. Pricl, P. La Colla, B. Secci, G. Collu, R. Loddo, Synthesis and in vitro evaluation of the anti-viral activity of N [4-(1H(2H)-benzotriazol-1(2)-yl)phenyl]alkylcarboxamides, Med. Chem. 2 (2006) 577-589.
271. G.D. Diana, T.R. Bailey, US Patent 5633388, (1997).
272. A. Carta, M. Loriga, S. Piras, G. Paglietti, M. Ferrone, M. Fermeglia, S. Pricl, P. La Colla, G. Collu, T. Sanna, R. Loddo, Synthesis and anti-picornaviridae in vitro activity of a new class of helicase inhibitors the N, N'-bis [4-(1H(2H)-benzotriazol-1(2)-yl)phenyl] alkyldicarboxamides, Med. Chem. 3 (2007) 520-532.
273. J.S.M. Peiris, S.T. Lai, L.L.M. Poon, Y. Guan, L.Y.C. Yam, W. Lim, J. Nicholls, W.K.S. Yee, M.T. Cheung, V.C. Cheng, Coronavirus as a possible cause of severe acute respiratory syndrome, Lancet 361 (2003) 1319-1325.
274. L.J. Stockman, R. Bellamy, P. Garner, SARS: systematic review of treatment effects, PLoS Med. 3 (2006) e343.
275. K. Chou, D. Wei, W. Zhong, Binding mechanism of coronavirus main protease with ligands and its implication to drug design against SARS, Biochem. Biophys. Res. Commun. 308 (2003) 148-151.
276. P.A. Rota, M.S. Oberste, S.S. Monroe, W.A. Nix, R. Campagnoli, J.P. Icenogle, S. Penaranda, B. Bankamp, K. Maher, M.H. Chen, S. Tong, A. Tamin, L. Lowe, M. Frace, J.L. DeRisi, Q. Chen, D. Wang, D.D. Erdman, T.C. Peret, C. Burns, T.G. Ksiazek, P.E. Rollin, A. Sanchez, S. Liffick, B. Holloway, J. Limor, K. McCaustland, M. Olsen-Rasmussen, R. Fouchier, S. Gunther, A.D. Osterhaus, C. Drosten, M.A. Pallansch, L.J. Anderson, W.J. Bellini, Characterization of a novel coronavirus associated with severe acute respiratory syndrome, Science 300 (2003) 1394-1399.
277. M.A. Marra, S.J. Jones, C.R. Astell, R.A. Holt, A. Brooks-Wilson, Y.S. Butterfield, J. Khattra, J.K. Asano, S.A. Barber, S.Y. Chan, A. Cloutier, S.M. Coughlin, D. Freeman, N. Girn, O.L. Griffith, S.R. Leach, M. Mayo, H. McDonald, S.B. Montgomery, P.K. Pandoh, A.S. Petrescu, A.G. Robertson, J.E. Schein, A. Siddiqui, D.E. Smailus, J.M. Stott, G.S. Yang, F. Plummer, A. Andonov, H. Artsob, N. Bastien, K. Bernard, T.F. Booth, D. Bowness, M. Czub, M. Drebot, L. Fernando, R. Flick, M. Garbutt, M. Gray, A. Grolla, S. Jones, H. Feldmann, A. Meyers, A. Kabani, Y. Li, S. Normand, U. Stroher, G.A. Tipples, S. Tyler, R. Vogrig, D. Ward, B. Watson, R.C. Brunham, M. Krajden, M. Petric, D.M. Skowronski, C. Upton, R.L. Roper, The genome sequence of the SARSassociated coronavirus, Science 300 (2003) 1399-1404.
278. U. Bacha, J. Barrila, A. Velazquez-Campoy, S.A. Leavitt, E. Freire, Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro, Biochemistry 43 (2004) 4906-4912.
279. R.P. Jain, H.I. Pettersson, J. Zhang, K.D. Aull, P.D. Fortin, C. Huitema, L.D. Eltis, J.C. Parrish, M.N. James, D.S. Wishart, J.C. Vederas, Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro, J. Med. Chem. 47 (2004) 6113-6116.
280. J. Zhang, H.I. Pettersson, C. Huitema, C. Niu, J. Yin, M.N. James, L.D. Eltis, J.C. Vederas, Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters, J. Med. Chem. 50 (2007) 1850-1864.
281. D.H. Goetz, Y. Choe, E. Hansell, Y.T. Chen, M. McDowell, C.B. Jonsson, W.R. Roush, J. McKerrow, C.S. Craik, Substrate specificity profiling and identification of a new class of inhibitor for the major protease of the SARS coronavirus, Biochemistry 46 (2007) 8744-8752.
282. C.Y. Chou, C.H. Chien, Y.S. Han, M.T. Prebanda, H.P. Hsieh, B. Turk, G.G. Chang, X. Chen, Thiopurine analogues inhibit papain-like protease of severe acute respiratory syndrome coronavirus, Biochem. Pharmacol. 75 (2008) 1601-1609.
283. C.Y. Wu, K.Y. King, C.J. Kuo, J.M. Fang, Y.T. Wu, M.Y. Ho, C.L. Liao, J.J. Shie, P.H. Liang, C.H. Wong, Stable benzotriazole esters as mechanism-based inactivators of the severe acute respiratory syndrome 3CL protease, Chem. Biol. 13 (2006) 261-268.
284. Y.F. Shan, S.F. Li, G.J. Xu, A novel auto-cleavage assay for studying mutational effects on the active site of severe acute respiratory syndrome coronavirus 3C-like protease, Biochem. Bioph. Res. Co. 324 (2004) 579-583.
285. K.H. Verschueren, K. Pumpor, S. Anemuller, S. Chen, J.R. Mesters, R. Hilgenfeld, A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters, Chem. Biol. 15 (2008) 597-606.
286. C. Huitema, J. Zhang, J. Yin, M.N. James, J.C. Vederas, L.D. Eltis, Heteroaromatic ester inhibitors of hepatitis A virus 3C proteinase: evaluation of mode of action, Bioorg. Med. Chem. 16 (2008) 5761-5777.
287. K. O'Connell, Use of palivizumab and infection control measures to control an outbreak of respiratory syncytial virus in a neonatal intensive care unit confirmed by real-time polymerase chain reaction, J. Hosp. Infect. 77 (2011) 338-342.
288. K.L. Yu, Y. Zhang, R.L. Civiello, K.F. Kadow, C. Cianci, M. Krystal, N.A. Meanwell, Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor, Bioorg. Med. Chem. Lett. 13 (2003) 2141-2144.
289. K.L. Yu, R.L. Civiello, M. Krystal, K.F. Kadow, N.A. Meanwell, Patent WO 00/04900, Chem. Abstr. 2000, 132 (2000).
290. G. Paglietti, V. Boido, F. Sparatore, Substituted benzimidazoles antiviral agents, Farm. Sci. 30 (1975) 505-507.
291. C. Cianci, K.L. Yu, K. Combrink, N. Sin, B. Pearce, A. Wang, R. Civiello, S. Voss, G. Luo, K. Kadow, E.V. Genovesi, B. Venables, H. Gulgeze, A. Trehan, J. James, L. Lamb, I. Medina, J. Roach, Z. Yang, L. Zadjura, R. Colonno, J. Clark, N. Meanwell, M. Krystal, Orally active fusion inhibitor of respiratory syncytial virus, Antimicrob. Agents Chem. 48 (2004) 413-422.
292. N.A. Meanwell, M. Krystal, Respiratory syncytial virus e the discovery and optimization of orally bioavailable fusion inhibitors, Drugs Fut. 32 (2007) 441-455.
293. K.L. Yu, Y. Zhang, R.L. Civiello, A.K. Trehan, B.C. Pearce, Z. Yin, K.D. Combrink, H.B. Gulgeze, X.A. Wang, K.F. Kadow, C.W. Cianci, M. Krystal, N.A. Meanwell, Respiratory syncytial virus inhibitors. Part 2: benzimidazol-2-one derivatives, Bioorg. Med. Chem. Lett. 14 (2004) 1133-1137.
294. M. Tonelli, G. Paglietti, V. Boido, F. Sparatore, F. Marongiu, E. Marongiu, P. La Colla, R. Loddo, Antiviral activity of benzimidazole derivatives. I. Antiviral activity of 1-substituted-2 [(benzotriazol-1/2-yl)methyl]benzimidazoles, Chem. Biodivers. 5 (2008) 2386-2401.
295. C. Weyer, C. Bogardus, D.M. Mott, R.E. Pratley, The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus, J. Clin. Invest. 104 (1999) 787-794.
296. L. Bialy, H. Waldmann, Inhibitors of protein tyrosine phosphatases: nextgeneration drugs? Angew. Chem. 44 (2005) 3814-3839.
297. Y.A. Puius, Y. Zhao, M. Sullivan, D.S. Lawrence, S.C. Almo, Z.Y. Zhang, Identification of a second aryl phosphate-binding site in protein-tyrosine phosphatase 1B: a paradigm for inhibitor design, Proc. Natl. Acad. Sci. USA 94 (1997) 13420-13425.
298. Y. Han, M. Belley, C.I. Bayly, J. Colucci, C. Dufresne, A. Giroux, C.K. Lau, Y. Leblanc, D. McKay, M. Therien, M.C. Wilson, K. Skorey, C.C. Chan, G. Scapin, B.P. Kennedy, Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl] phosphonic acid, a potent and orally active small molecule PTP1B inhibitor, Bioorg. Med. Chem. Lett. 18 (2008) 3200-3205.
299. C.K. Lau, C.I. Bayly, J.Y. Gauthier, C.S. Li, M. Therien, E. Asante-Appiah, W. Cromlish, Y. Boie, F. Forghani, S. Desmarais, Q. Wang, K. Skorey, D. Waddleton, P. Payette, C. Ramachandran, B.P. Kennedy, G. Scapin, Structure based design of a series of potent and selective non peptidic PTP-1B inhibitors, Bioorg. Med. Chem. Lett. 14 (2004) 1043-1048.
300. G. Scapin, S.B. Patel, J.W. Becker, Q. Wang, C. Desponts, D. Waddleton, K. Skorey, W. Cromlish, C. Bayly, M. Therien, J.Y. Gauthier, C.S. Li, C.K. Lau, C. Ramachandran, B.P. Kennedy, E. Asante-Appiah, The structural basis for the selectivity of benzotriazole inhibitors of PTP1B, Biochemistry 42 (2003) 11451-11459.
301. N. Liang, Y. Li, Z. Ge, Analyses based on 3D-QSAR/QSSR of PTP-1B selective inhibitor-benzotriazole derivatives, Huaxue Xuebao 67 (2009) 735-745.
302. D. Patel, M. Jain, S.R. Shah, R. Bahekar, P. Jadav, B. Darji, Y. Siriki, D. Bandyopadhyay, A. Joharapurkar, S. Kshirsagar, H. Patel, M. Shaikh, K.V. Sairam, P. Patel, Discovery of orally active, potent, and selective benzotriazole-based PTP1B inhibitors, Chem. Med. Chem. 6 (2011) 1011-1016.
303. P.A. White, L.D. Claxton, Mutagens in contaminated soil: a review, Mutat. Res. 567 (2004) 227-345.
304. H. Nukaya, J. Yamashita, K. Tsuji, Y. Terao, T. Ohe, H. Sawanishi, T. Katsuhara, K. Kiyokawa, M. Tezuka, A. Oguri, T. Sugimura, K. Wakabayashi, Isolation and chemical-structural determination of a novel aromatic amine mutagen in water from the Nishitakase River in Kyoto, Chem. Res. Toxicol. 10 (1997) 1061-1066.
305. A. Oguri, T. Shiozawa, Y. Terao, H. Nukaya, J. Yamashita, T. Ohe, H. Sawanishi, T. Katsuhara, T. Sugimura, K. Wakabayashi, Identification of a 2-phenylbenzotriazole (PBTA)-type mutagen, PBTA-2, in water from the Nishitakase River in Kyoto, Chem. Res. Toxicol. 11 (1998) 1195-1200.
306. H. Nukaya, T. Shiozawa, A. Tada, Y. Terao, T. Ohe, T. Watanabe, M. Asanoma, H. Sawanishi, T. Katsuhara, T. Sugimura, K. Wakabayashi, Identification of 2 [2-(acetylamino)-4-amino-5-methoxyphenyl]-5-amino-7-bromo-4-chloro-2H-benzotria zole (PBTA-4) as a potent mutagen in river water in Kyoto and Aichi prefectures, Japan, Mutat. Res. 492 (2001) 73-80.
307. T. Watanabe, H. Nukaya, Y. Terao, Y. Takahashi, A. Tada, T. Takamura, H. Sawanishi, T. Ohe, T. Hirayama, T. Sugimura, K. Wakabayashi, Synthesis of 2-phenylbenzotriazole-type mutagens, PBTA-5 and PBTA-6, and their detection in river water from Japan, Mutat. Res. 498 (2001) 107-115.
308. T. Shiozawa, A. Tada, H. Nukaya, T. Watanabe, Y. Takahashi, M. Asanoma, T. Ohe, H. Sawanishi, T. Katsuhara, T. Sugimura, K. Wakabayashi, Y. Terao, Isolation and identification of a new 2-phenylbenzotriazole-type mutagen (PBTA-3) in the Nikko river in Aichi, Japan, Chem. Res. Toxicol. 13 (2000) 535-540.
309. T. Shiozawa, K. Suyama, K. Nakano, H. Nukaya, H. Sawanishi, A. Oguri, K. Wakabayashi, Y. Terao, Mutagenic activity of 2-phenylbenzotriazole derivatives related to a mutagen, PBTA-1, in river water, Mutat. Res. 442 (1999) 105-111.
310. T. Motoyama, K. Okamoto, I. Kukita, M. Hamaguchi, Y. Kinoshita, H. Ogawa, Possible role of increased oxidant stress in multiple organ failure after systemic inflammatory response syndrome, Crit. Care Med. 31 (2003) 1048-1052.
311. C.M. Jamkandi, J.I. Disouza, Evaluation of antioxidant activity for some benzotriazole substituted with N-phenylacetamide and acetylcarbamic acid derivatives, Intern. J. Pharm. Pharm. Sci. 5 (2013) 249-253.
312. J.M. Mathews, J.R. Bend, N-alkylaminobenzotriazoles as isozyme-selective suicide inhibitors of rabbit pulmonary microsomal cytochrome P-450, Mol. Pharmacol. 30 (1986) 25-32.
313. L.C. Knickle, R.M. Philpot, J.R. Bend, N-aralkylated derivatives of 1-aminobenzotriazole are potent isozyme-and lung-selective mechanismbased inhibitors of Guinea pig cytochrome P-450 in vivo, J. Pharmacol. Exp. Ther. 270 (1994) 377-385.
314. K.J. Woodcroft, E.W. Szczepan, L.C. Knickle, J.R. Bend, Three N-aralkylated derivatives of 1-aminobenzotriazole as potent and isozyme-selective, mechanism-based inhibitors of guinea pig pulmonary cytochrome P-450 in vitro, Drug Metab. Dispos. 18 (1990) 1031-1037.
315. K.J. Woodcroft, J.R. Bend, N-aralkylated derivatives of 1-aminobenzotriazole as isozyme-selective, mechanism-based inhibitors of guinea pig hepatic cytochrome P-450 dependent monooxygenase activity, Can. J. Physiol. Pharm. 68 (1990) 1278-1285.
316. Y. Hirokawa, H. Yamazaki, N. Yoshida, S. Kato, A novel series of 6-methoxy-1H-benzotriazole-5-carboxamide derivatives with dual antiemetic and gastroprokinetic activities, Bioorg. Med. Chem. Lett. 8 (1998) 1973-1978.
317. T. Yoshikawa, Y. Mine, K. Morikage, N. Yoshida, Pharmacological profile of AS-9705, a novel benzotriazolecarboxamide derivative, as a gastroprokinetic agent with potent anti-emetic activity, Arzneim 53 (2003) 98-106.